1. Home
  2. PCT vs GERN Comparison

PCT vs GERN Comparison

Compare PCT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PureCycle Technologies Inc.

PCT

PureCycle Technologies Inc.

HOLD

Current Price

$11.27

Market Cap

2.3B

Sector

Utilities

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

821.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCT
GERN
Founded
2015
1990
Country
United States
United States
Employees
174
258
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
821.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PCT
GERN
Price
$11.27
$1.26
Analyst Decision
Buy
Hold
Analyst Count
3
3
Target Price
$13.00
$2.17
AVG Volume (30 Days)
4.7M
14.2M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$380.44
$26.91
Revenue Next Year
$203.33
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$1.04
52 Week High
$17.37
$2.01

Technical Indicators

Market Signals
Indicator
PCT
GERN
Relative Strength Index (RSI) 67.12 32.94
Support Level $7.87 $1.24
Resistance Level $15.13 $1.29
Average True Range (ATR) 0.85 0.09
MACD 0.13 -0.02
Stochastic Oscillator 66.58 10.42

Price Performance

Historical Comparison
PCT
GERN

About PCT PureCycle Technologies Inc.

PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: